Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | PER2 | O15055 | 2/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715212 | 0.89 | TSHR (0.46) | TSHRPER2CRY2APEX1BLM | |
| SCHEMBL27517863 | 0.78 | TSHR (0.44) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL7386709 | 0.77 | TSHR (0.44) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL13632872 | 0.76 | PER2 (0.43) | PER2CRY2EHMT2MEN1KMT2A | |
| SCHEMBL21389411 | 0.75 | PER2 (0.43) | PER2CRY2BLMOPRM1OPRL1 | |
| SCHEMBL12600979 | 0.74 | PER2 (0.42) | PER2CRY2EHMT2MEN1KMT2A | |
| SCHEMBL21389498 | 0.73 | KMT2A (0.36) | TSHRPER2CRY2ALDH1A1L3MBTL1 | |
| SCHEMBL15438497 | 0.73 | KMT2A (0.42) | PER2CRY2ALDH1A1KMT2AKDM4E | |
| SCHEMBL3548171 | 0.72 | TSHR (0.43) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL19852844 | 0.72 | TSHR (0.38) | TSHRAPEX1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-3986559-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2020260871-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | TSHR 4598/4885PER2 2495/4885CRY2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.